Ros Eeles, PhD, FRCP, FRCR, presented “The BARCODE 1 Study: Enrichment of Prostate Cancer Detection in Those with Higher Polygenic Risk” during the 8th Global Summit on Precision Diagnosis and Treatment of Prostate Cancer on October 8, 2024.
How to cite: Eeles, Ros. “The BARCODE 1 Study: Enrichment of Prostate Cancer Detection in Those with Higher Polygenic Risk.” October 8, 2024. Accessed Dec 2024. https://grandroundsinurology.com/the-barcode-1-study-enrichment-of-prostate-cancer-detection-in-those-with-higher-polygenic-risk/
The BARCODE 1 Study: Enrichment of Prostate Cancer Detection in Those with Higher Polygenic Risk – Summary
Ros Eeles, PhD, FRCP, FRCR, introduces the BARCODE 1 study, which explores the enrichment of prostate cancer detection using polygenic risk scores (PRS) and addresses challenges with traditional screening methods.
In this six-minute presentation, Eeles interprets the study’s results, concluding that PRS offers a robust, one-time genetic test to guide targeted screening, detecting more significant cancers without contributing to overdiagnosis.
The Global Summit on Precision Diagnosis and Treatment of Prostate Cancer is a unique multi-disciplinary forum organized to inform the key health care stakeholders about the emerging advances in clinical case and research and create a consensus-based vision for the future of precision care and educational and research strategy for its realization. The mission of the Summit is to fill the currently existing gap between the key experts of in vivo imaging, the world authorities in the in vitro fluid- and tissue-based molecular diagnostics, including genomics, and thought leaders in the development of novel observation strategies (e.g., active surveillance, or AS) and therapeutic interventions.
ABOUT THE AUTHOR
Professor Rosalind (Ros) Eeles is a clinician as well as a scientist, running both a laboratory at The Institute of Cancer Research, London, and a Cancer Genetics and Uro-Oncology Clinic at the ICR’s partner hospital, The Royal Marsden NHS Foundation Trust. She trained at The University of Cambridge and St Thomas’ Hospital Medical School.
After completing her higher medical training, Professor Eeles trained in Clinical Oncology at The Royal Marsden and then in cancer genetics with Professor Bruce Ponder. She then spent a year as an Assistant Professor at the University of Utah in Salt Lake City, United States, where she studied hereditary prostate cancer, worked in research in cancer genetics and had oncology clinical experience.
She has sat on several genetics advisory committees, both national and international, including the Department of Health Genetics Advisory Committee, has given evidence to the House of Lords’ Select Committee on genomic medicine and edited a special edition of the Familial Cancer journal on delivering cancer genetics services.
She is now a Professor of Oncogenetics at The ICR and an Honorary Consultant in Clinical Oncology and Cancer Genetics at The Royal Marsden NHS Foundation Trust.
